TLX.AX Stock — Price, Charts & Analysis

Telix Pharmaceuticals Limited (TLX.AX) has no trailing P/E shown and a forward P/E of 852.18x. This places TLX.AX in a premium earnings multiple territory based on the valuation data currently available on Worldtickers.

TLX.AX trades with 852.18x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether TLX.AX looks overvalued or undervalued.

TLX.AX's P/E of 852.18x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

TLX.AX's trailing EPS is -A$0.03 and forward EPS is A$0.02.

EPS, or earnings per share, shows how much profit Telix Pharmaceuticals Limited generated for each share. TLX.AX's trailing EPS is -A$0.03, and investors usually prefer EPS that is positive and growing over time.

Telix Pharmaceuticals Limited has a market cap of A$5.57B, making TLX.AX a mid-cap stock based on the current market value shown on Worldtickers.

TLX.AX's latest stock price on Worldtickers is A$16.43. The latest move is -A$0.95 or -5.47%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

TLX.AX's quote includes a latest price of A$16.43. The market open is A$16.62. Previous close is A$17.38. The intraday range is A$15.73 to A$16.76.

TLX.AX is down in the latest quote, with a move of -A$0.95 or -5.47%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

TLX.AX generated A$803.79M in trailing revenue. Revenue growth is 49.30%, which helps show whether demand is expanding or slowing.

TLX.AX's revenue growth is 49.30%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

No, TLX.AX does not show positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is -A$7.13M.

Gross margin is 47.50%. Margins show how efficiently Telix Pharmaceuticals Limited turns revenue into profit.

Telix Pharmaceuticals Limited carries A$467.11M and holds A$141.87M in cash.

TLX.AX holds A$141.87M on its balance sheet.

TLX.AX's book value per share is A$1.78.

Institutions hold 33.10% of TLX.AX shares. Insiders hold 16.90% of shares. Ownership mix helps investors understand how much of Telix Pharmaceuticals Limited is held by professional investors and company insiders.

TLX.AX has 338.78M shares outstanding. Float shares are 272.81M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for TLX.AX, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for TLX.AX is A$0.02. Revenue growth is 49.30%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

TLX.AX's trailing EPS is -A$0.03. Forward EPS is A$0.02. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

TLX.AX is in the Healthcare sector. Its earnings multiple is 852.18x. Its latest displayed growth metric is 49.30%. Compare these figures with sector peers before deciding whether Telix Pharmaceuticals Limited is stronger or weaker than average.

TLX.AX trades at A$16.43. The stock trades at 852.18x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Telix Pharmaceuticals Limited's fundamentals.

TLX.AX risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.60, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

TLX.AX should be compared with companies in Biotechnology. Its earnings multiple is 852.18x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Telix Pharmaceuticals Limited (TLX.AX) operates in Healthcare, specifically Biotechnology. Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treati

TLX.AX trades on ASX. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

TLX.AX stock is priced in AUD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Telix Pharmaceuticals Limited's official website listed on Worldtickers is telixpharma.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Telix Pharmaceuticals Limited employs about 1.12K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Telix Pharmaceuticals Limited is headquartered in North Melbourne, VIC, Australia. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

TLX.AX is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

TLX.AX has traded between A$8.26 and A$19.07 over the past 52 weeks. At A$16.43, it is 13.84% below the high and 98.91% above the low. The 52-week range helps gauge long-term price momentum.

TLX.AX is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is A$15.64 and its 200-day moving average is A$13.44.

TLX.AX's RSI is 54.36. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

TLX.AX's latest RSI reading is 54.36, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for TLX.AX is near A$13.95. Key resistance is near A$18.13. Breaks above resistance or below support can change the short-term technical setup.

TLX.AX's nearest reported support level is A$13.95. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

TLX.AX's nearest reported resistance level is A$18.13. A breakout above resistance can improve momentum, especially when volume confirms the move.

TLX.AX trades about 1.98M shares daily on average. The latest displayed volume is 1.93M shares. Volume helps show liquidity and whether trading interest is unusually high or low.

TLX.AX's MACD is 0.11, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

TLX.AX is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 54.36 (neutral). MACD is bullish. Nearest support is around A$13.95. Resistance is around A$18.13. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is A$15.73 (4.46% from price). MA50 is A$15.64 (5.05% from price). MA200 is A$13.44 (22.28% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. TLX.AX's MA20 is A$15.73. MA50 is A$15.64. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

TLX.AX's pivot is near A$17.35. Support is near A$13.95. Resistance is near A$18.13. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for TLX.AX is near A$15.88. These levels help define risk and possible follow-through zones after a breakout or breakdown.

TLX.AX's Bollinger range is roughly A$13.32 to A$18.14. Band width is near 30.69%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

TLX.AX's ATR-based typical daily range is about 4.66%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 1.93M shares. Average volume is about 1.98M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

TLX.AX's all-time high shown on Worldtickers is A$31.97. Its all-time low is A$0.46. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

TLX.AX has a beta of 0.60, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.